

Title	The gut microbiome and atherosclerosis: current knowledge and clinical potential
Authors	Ahmad, Adilah; Dwivedi, Girish; O'Gara, Fergal; Caparros-Martin, Jose; Ward, Natalie
Publication date	2019-08-30
Original Citation	Ahmad, A., Dwivedi, G., O'Gara, F., Caparros-Martin, J. and Ward, N. (2019) 'The gut microbiome and atherosclerosis: current knowledge and clinical potential', American Journal of Physiology - Heart and Circulatory Physiology. doi: 10.1152/ajpheart.00376.2019
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://www.physiology.org/doi/abs/10.1152/ajpheart.00376.2019 - 10.1152/ajpheart.00376.2019
Rights	© 2019, American Journal of Physiology-Heart and Circulatory Physiology. All rights reserved.
Download date	2023-05-05 05:02:47
Item downloaded from	http://hdl.handle.net/10468/8462

The gut microbiome and cardiovascular disease: current knowledge and clinical potential

Adilah F. Ahmad^{1,2}, Girish Dwivedi^{1,2,3}, Fergal O’Gara^{4,5,6,7}, Jose Caparros-Martin^{4,5},
Natalie C. Ward^{1,8}

¹Medical School, University of Western Australia, Perth, Australia

²Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Perth, Australia

³Department of Cardiology, Fiona Stanley Hospital, Murdoch, Australia

⁴School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Australia

⁵Curtin Health Innovation Research Institute, Curtin University, Perth, Australia

⁶BIOMERIT Research Centre, School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland.

⁷Telethon Kids Institute, Children’s Hospital, Perth, Australia. WA6009

⁸School of Public Health, Curtin University, Perth Australia

Address for correspondence:

Dr NC Ward

School of Public Health

Curtin University

Tel: +61 8 9266 4188

Email: natalie.ward@curtin.edu.au

Word Count: 7851

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is populated by a diverse community of microbes, dominated by bacteria, but also including viruses and fungi. The largest and most complex of these communities is located in the gastrointestinal system and with their associated genome, are known as the gut microbiome. Gut microbiome perturbations and related dysbiosis have been implicated in the progression and pathogenesis of CVD, including atherosclerosis, hypertension and heart failure. Although there have been advances in the characterisation and analysis of the gut microbiota and associated bacterial metabolites, the exact mechanisms through which they exert their action is not well understood. This review will focus on the role of the gut microbiome and associated functional components in the development and progression of atherosclerosis. Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD are also discussed.

Keywords: Atherosclerosis; cardiovascular disease, dysbiosis, microbiome, short chain fatty acids, TMAO

56 **List of abbreviations:**

57

58 AAA: abdominal aortic aneurysm

59 ACS: acute coronary syndrome

60 AMPK: adenosine monophosphate-activated protein kinase

61 ApoE^{-/-} : apolipoprotein E knockout

62 BA: bile acid

63 CAD: coronary artery disease

64 CLA: conjugated linoleic acids

65 CVD: cardiovascular disease

66 FOS: fructooligosaccharides

67 FXR: Farnesoid X receptor

68 GPR: G protein-coupled receptor

69 LDL-C: low density lipoprotein-c

70 PAD: peripheral arterial disease

71 SCFA: short chain fatty acid

72 TGR: Takeda G protein coupled receptor

73 TLR: toll-like receptors

74 TMA: trimethylamine

75 TMAO: trimethylamine-N- oxide

76 16S rRNA: 16S ribosomal ribonucleic acid

77

Introduction

Cardiovascular disease (CVD) is the leading cause of death and disability globally (60). The human gut is populated by a diverse and complex community of bacteria, viruses, fungi and protozoa, which along with their genome, are collectively known as the gut microbiome (90). An alteration in gut microbiome composition and linked functionality is known as microbial dysbiosis. Studies have shown that gut microbiota interact with the host, contributing to host health and disease status. Although there is a large interindividual variation in terms of microbial composition, healthy individuals share core functional capabilities (146). However, several disease states, including CVD, are associated with microbial dysbiosis (78). There is increasing evidence in CVD demonstrating an alteration in diversity and composition of the gut microbiome and its associated metabolites which may influence the pathogenesis and progression of diseases such as atherosclerosis [acute coronary syndrome (ACS) and stroke], heart failure and hypertension. The complex host-microbiome interaction influences the synthesis and release of several metabolites including trimethylamine-N-oxide (TMAO), bile acids (BA) and short chain fatty acids (SCFA), which impact host homeostasis (139). While recent advances in genomic and metabolomics have allowed the accurate characterisation and quantification of these microbes and their metabolites, the exact mechanisms of their action remain unclear. Interventions targeting the microbiome could provide new avenues for the management and treatment of CVD patients (138). In this review we will discuss the development and progression of atherosclerosis, the contribution of the microbiota, specifically the gut bacteria, and the potential for targeting the microbiome and its associated components as novel therapeutic options.

The gut microbiome

A complex and dynamic community of microbes live in the human gastrointestinal tract, a nutrient rich microenvironment conducive for the growth of microorganisms. (146). There is a dominance of bacteria in this environment belonging to five main phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia (Figure 1) (177). There is large interindividual variation in the composition, diversity and abundance of bacteria and microbes, predominantly due to host genome factors as well as environmental parameters like lifestyle, diet, hygiene, health, medication such as antibiotics and the use of prebiotics and probiotics (18). There is a symbiotic relationship between the host and the microbiota,

developing from birth through to adulthood (76). The symbiotic relationship of the microbiome and the host promote the growth of beneficial commensal bacteria while inhibiting the overgrowth of pathogenic ones (102).

The normal physiological functions of the gut microbiome include fermentation of indigestible dietary substances (87), synthesis of certain vitamins (122), energy metabolism via SCFA production (13) and the regulation of the intestinal epithelial mucosal barrier (73). If disrupted, this barrier will result in 'leakage' allowing bacterial translocation and an increase in exposure to bacterial derived products such as circulating endotoxins.

The gut microbiome has a very diverse role and can have distal effects in the body. There is a complex interplay between the gut microbiome and the health and function of the host via production and release of important metabolites including SCFA, BAs and TMAO as well as influencing various host metabolic pathways (139). These metabolites can be absorbed into the bloodstream via the intestinal epithelium, thus influencing the function of several distal organs and body systems (127).

Atherosclerosis

Atherosclerosis is a chronic inflammatory condition resulting from initial endothelial injury followed by lipid build-up and plaque formation in the arteries. Risk factors for atherosclerosis include hypercholesterolaemia, hypertension, diabetes mellitus, obesity, and a sedentary lifestyle (113). Cellular events that contribute to the initiation and progression of atherosclerosis involve; lipid migration to the inner layer of the arterial wall – the endothelium, adhesion of circulating monocytes and lymphocytes to the endothelial cells, migration of monocytes into the sub-endothelial space and acquiring macrophage characteristics and converting into foam cells (113). Low density lipoprotein (LDL) particles undergo modification, primarily through oxidation, becoming strong chemo attractants (113). These processes, which involve cell adhesion, migration, differentiation, further proliferation and interaction with the extra cellular matrix, are controlled and regulated by a cascade of cytokines and growth regulatory peptides and ultimately lead to the accumulation of cholesterol and the formation of fatty streaks (113). Vascular smooth muscle cells also migrate to the endothelium and proliferate, with additional accumulation of macrophages,

modified LDL and inflammatory cells, together forming the atherosclerotic plaque (11). The plaque consists of various cells (endothelial cells, foam cells, macrophages and leukocytes), accumulated lipids (cholesterol, triglycerides), calcified regions and a necrotic core (113). Vascular dysfunction and hypertension contribute to vessel damage via mechanisms involving an increase in inflammation and LDL, causing plaque formation and build up in arterial walls progressing to atherosclerosis (11). Atherosclerosis progresses to various cardiovascular diseases such as ACS, stroke, AAA and ultimately heart failure.

Microbiota and their metabolites profoundly modulate the progression of atherosclerosis, the most common cause of ACS, stroke and peripheral vascular disease (Figure 2) (74). However, despite this, the mechanisms of action as to how the gut microbiota contribute to atherosclerosis remain to be elucidated. Recent reviews have highlighted the potential role of dysbiosis in several disease states, including atherosclerosis, heart failure, hypertension and diabetes mellitus (3, 145). In these states the gut bacteria diversity, composition and associated metabolic functions can change, leading to disruption of vital physiological processes, including inflammation, lipid metabolism, bacterial translocation and glucose homeostasis which may all contribute to disease development and progression.

Changes in the microbiome composition may also contribute to the development and progression of CVD, with alterations in the ratio of the key phyla of Firmicutes to Bacteroidetes proposed as a potential risk factor of CVD (20, 32, 135). Similarly, there is a correlation between various gut microbiome metabolite levels, including TMAO, SCFA and BA and the pathogenesis of CVD. Finally, risk factors and associated symptoms of CVD may cause further microbial dysbiosis, including accumulation of toxic metabolites (such as TMAO) and pathogenic bacterial species (73, 146, 177).

In the gut, symptomatic atherosclerotic patients had a greater abundance of *Collinsella* compared to healthy controls (48, 68). However, several of these studies were limited by their small sample sizes (<30) and thus further research is required. A recent metagenome wide association study from 218 individuals with atherosclerosis and 187 healthy controls observed that the gut microbiome deviates from a healthy status by an increase in the relative abundance of Enterobacteriaceae (including *Escherichia coli*, *Enterobacter aerogenes* and *Klebsiella* spp.) and *Streptococcus* spp (Table 1). Functionally, this impacts metabolism and

transport of molecules such as TMAO (64). These data suggest that the gut microbiome may be more proinflammatory in patients with CVD (64).

Carotid arteries

Carotid atherosclerosis is linked to an increased risk of cardiovascular events such as stroke and ACS (40). Stroke is divided into two categories; ischemic stroke which occurs as a result of a blockage in a blood vessel supplying blood to the brain and haemorrhagic stroke, occurring from the rupture of a weakened blood vessel in the brain (6). Ischemic stroke accounts for 70 – 80% of all strokes (6). There is a bidirectional relationship between the brain and gut microbiota via vagus nerve activity and the enteric nervous system (26). During ischemic stroke, the brain produces molecules which signal damage, including damage associated molecular proteins and cytokines. The damage associated molecular proteins and cytokines produced in ischemic brain tissue are released into the circulation and communicate with immune and lymphoid organs leading to systemic inflammatory and immune responses (26). The gut will also release cytokines and gut inflammatory and immune cells will travel to the site of brain injury.

After ischemic or haemorrhagic stroke, 50% of patients experience gastro intestinal issues, including gut microbiota dysbiosis, “leaky” gut, increased gut motility, disorganization and gut haemorrhage (169) as well as a reduced diversity and composition of the gut microbiota (173). As a result, intestinal inflammatory and immune responses are triggered (137). These patients have increased mortality rates and worsening neurological function with poor outcomes. This altered immune homeostasis largely occurs due to the gut microbiota’s role in communicating with intestinal epithelial cells, dendritic cells, B and T lymphocytes, mononuclear phagocytes and innate lymphoid cells (67). Zeng and colleagues investigated the association of the gut microbiome with high and low risk stroke and noted enrichment in opportunistic pathogens (e.g. *Enterobacteriaceae* and *Veillonellaceae*) and depleted abundance of butyrate producing bacteria (e.g. *Lachnospiraceae* and *Ruminococcaceae*) with reduced faecal butyrate levels in patients with a high risk of stroke (179). Many aspects of gut microbiota dysbiosis and modulation of inflammatory and immune responses have been implicated in stroke. However, what these effects signify in reality for stroke therapy remains to be investigated.

Coronary arteries

Coronary artery disease (CAD) involves a narrowing of the coronary arteries supplying blood to the heart due to plaque build-up, thereby reducing blood flow. Atherosclerosis is the main pathophysiological basis of CAD. A small study found CAD patients had alterations in the gut microbiota, including an increase in Lactobacillales (from Firmicutes phylum and consisting of the genera *Lactobacillus*, *Streptococcus* and *Enterococcus*) whereas the phylum Bacteroidetes (composed of the genera *Bacteroides* and *Prevotella*) was reduced (42). *Bacteroides fragilis* promotes regulatory T-cell function in mucosal T-cell homeostasis (99). A recent study in CAD revealed a decreased microbial diversity and composition, as reflected by enrichment in *Escherichia/Shigella* and *Enterococcus*, while *Faecalibacterium*, *Subdoligranulum*, *Roseburia* and *Eubacterium rectale* were depleted (180). *Faecalibacterium* has an important anti-inflammatory role (89, 93), while *Roseburia* are important for SCFA production which potentially depletes energy supply for intestinal cells thus negatively affecting the gut barrier (54, 76). In atheromatous plaques of patients with CAD, there was an enhanced bacterial diversity of *Staphylococcus* species, *Proteus vulgaris*, *Klebsiella pneumoniae* and *Streptococcus* sp. Although, there was a predominant bacterial signature in these plaques, it is not proof that the gut microbiota plays a causal role in atherosclerosis. Instead it has been suggested that the presence of the bacteria could contribute to atherosclerosis development and/or progression (107).

ACS refers to a group of conditions including, unstable angina and acute myocardial infarction, and is usually characterised by a reduced blood flow to the heart muscle usually due to blockage (44). ACS is associated with inflammation, which plays a role in its pathogenesis. Evidence suggests that microbial dysbiosis may have an impact on several inflammatory or immune disorders via activating proinflammatory responses. Indeed, bacterial DNA was present on epicardial adipose tissue obtained during coronary artery bypass grafting in patients with ACS. This suggests that the epicardial adipose tissue environment is susceptible to microbial colonization, stimulating proinflammatory responses involved in vascular inflammation and plaque formation and instability. However, there is agreement that further research is warranted to provide more clarity to this important area (111).

Abdominal aortic aneurysm

Abdominal aortic aneurysm (AAA) is a localised swelling of the walls of the abdominal aorta, the rupture of which can be fatal. Pathogenesis of AAA includes complex inflammatory pathways, extracellular matrix disruption, inflammation, thrombosis, haemodynamic forces and associated signalling molecules (58). Atherosclerosis is an important and independent risk factor for AAA (155) as patients with AAA frequently have atherosclerosis and there is an association of coronary heart disease and peripheral artery disease with AAA (57). An investigation of atherosclerotic plaques from vascular biopsies in patients with vascular diseases (including AAA), with and without chronic periodontitis, detected bacterial DNA in 95%, with most biopsies comprising DNA from multiple bacterial species (5). This reinforces recent findings that suggest more than one bacterial species are involved with CVD (41, 91). Although finding bacterial DNA in atherosclerotic plaques is well established, it is not clear whether an infection initiates or promotes its formation. Animal models have identified microorganisms such as *Aggregatibacter actinomycetemcomitans*, *Helicobacter pylori*, *Chlamydomphila perfringens* and *Porphyromonas gingivalis*, which may contribute to increasing lesion areas in atherosclerosis (120). However, further research and validation in humans is required. In addition, gut microbiota function is affected by surgical abdominal aortic repair, which involves aortic clamping and can result in negative changes in intestinal permeability, which may also contribute to disease progression (109).

Peripheral artery disease and mesenteric ischemia

Peripheral artery disease (PAD) is characterised by reduced blood flow to the periphery, is a common consequence of systemic atherosclerosis and is associated with significantly higher risks of cardiovascular mortality. In patients with stable PAD, elevated plasma TMAO, a proatherogenic gut microbiota metabolite, was found to be a significant predictor of 5 year all-cause mortality risk, independent of traditional risk factors (131).

Mesenteric ischemia occurs as a result of reduced blood supply to the mesenteries supplying the small intestine. The gut microbiome plays a key role in mesenteric ischemia via Toll-like receptors (TLR) which recognise constituent molecules of bacteria and contribute to maintenance of the intestinal environment by playing a key role in the innate immune system

(103). The TLR signalling pathway, specifically TLR2 and TLR4, activate inflammatory responses, such as the release of tumour necrosis factor- α . Oxidative stress caused by reactive oxygen species and free radicals, the source of which are neutrophils and macrophages, also affect the intestine during ischemia (103). Neutrophils and macrophages release reactive oxygen species and free radicals to sterilize invading bacteria, however, excess production can cause local tissue injury (103). Prevention of oxidative stress is useful for treatment of mesenteric ischemia. Previous studies showed heme oxygenase-1 plays a protective role in mesenteric ischemia and reperfusion, by preventing oxidation (85, 168).

Gut microbiome metabolites

Trimethylamine-N-oxide

The gut microbiota is known to be involved in the synthesis of proatherogenic metabolites, namely TMAO (Figure 3) (100). The breakdown of dietary substances rich in phosphatidylcholine, choline or carnitine (from red meat, fish and eggs) forms trimethylamine (TMA), the precursor to TMAO (84). TMA is absorbed in the intestine and converted via the hepatic enzyme flavin monooxygenase 3 to TMAO, a plasma metabolite released into the bloodstream and eventually cleared by the kidneys (76, 178). TMAO is a biologically active molecule and has been shown to be a predictor of ACS, stroke and death, likely through a proatherogenic pathway (74, 84, 178). When mice were supplemented with chronic dietary L-carnitine, there was an alteration in caecal microbial composition and increased synthesis of TMA and TMAO and enhanced atherosclerosis, however, this was not seen when intestinal microbiota was concurrently suppressed (74). In fact, mice with intact gut microbiota had a reduction in *in vivo* reverse cholesterol transport when supplemented with either carnitine or choline (74), reinforcing the role of the gut microbiota in promoting atherosclerosis via the metabolism of L-carnitine, found in red meat. Evidence shows that individuals at higher risk for stroke and CVD have elevated TMAO levels as well as TMAO precursors (178). This was further reinforced when plaque progression and atherogenesis was promoted in apolipoprotein E knockout (ApoE^{-/-}) mice who were administered TMAO precursors or TMAO (55). Similarly, the administration of 3,3-dimethyl-1-butanol, a TMA inhibitor prevented cardiac dysfunction caused by a high sugar and high fat western diet (30).

Studies have demonstrated a correlation between gut microbiota metabolism of TMAO and risk of CVD (74, 84, 147, 148, 165), with a recent meta-analysis revealing a 67% increased

risk of developing CVD with high TMAO levels. Furthermore, for every 10 $\mu\text{mol/L}$ increase in TMAO, there was a 7.6% increase in all-cause mortality (127). TMAO enhances atherosclerosis via vascular inflammation, monocyte endothelial cell interactions and endothelial dysfunction as well as stimulating foam cell formation and atherosclerotic plaque progression (92, 130, 142). TMAO has been shown to activate inflammatory pathways within the vasculature, leading to leukocyte activation and atherosclerosis (130). TMAO levels were also elevated in individuals presenting with ACS and showed a dose-dependent relationship between increased risk of major adverse cardiac events and long-term mortality (84). TMAO has also been shown to play a role in promoting platelet hyperresponsiveness and thrombosis potential (181). TMAO acts to promote platelet reactivity through stimulus dependent calcium signalling, thereby increasing the risk of incident thrombotic events (181, 182). ApoE^{-/-} mice with TMAO supplemented in their diet had enhanced aortic lesions (165). Human studies have also reinforced the role of TMAO in CVD. In a prospective, observational study of heart failure, stable CAD and healthy subjects, plasma TMAO, choline and betaine were elevated in chronic HF patients compared to controls (156). Similarly, in myocardial infarction patients, TMAO independently predicted death at 2 years [292 events, hazard ratio 1.21 (95% CI, 1.03-1.43, P = 0.023)] (143). A study by Tang and colleagues revealed a correlation between elevated TMAO levels and an increased risk of major adverse cardiac events (148).

Bile Acid

BAAs are synthesised from cholesterol in the liver in a multistep processes involving several enzymes and are vital in the absorption of dietary fats in the intestine (78). Primary BAAs are secreted into the duodenum and play a role in emulsifying lipid-soluble dietary substances and vitamins to facilitate digestion and absorption (176). Other features of BAAs include their strong microbial activity (176) and their function as signalling molecules, acting as ligands for nuclear receptors, thus effecting metabolism. An example is the activation of the 'Farnesoid-X-receptor' (FXR), which supresses the action of cholesterol 7 α -hydroxylase enzyme, which is important in the formation of primary BAAs from its cholesterol precursor (78).

In the intestine, gut microbiota modify primary BAAs via bacterial salt hydrolase activity, which remove the -OH groups, turning them into secondary BAAs (167). Primary BAAs are

toxic to bacteria, hence making the BA more insoluble provide bacteria with a mechanism to reduce toxicity. Further modification of BAs by the gut microbiota may occur before being returned to the liver for re-conjugation and return to circulation (122). BAs are a vital pathway for cholesterol elimination via excretion in faeces, thereby decreasing circulating cholesterol levels and risk of plaque build-up (78). The gut microbiome can decrease BA synthesis rate, thus increasing the plasma levels of LDL and increasing the risk of atherosclerosis (126).

Short chain fatty acid

Short chain fatty acids such as acetate, butyrate and propionate are produced as a result of the fermentation of indigestible dietary fibres in the gut by the microbiota (47). They are straight chain saturated fatty acids composed of less than six carbon atoms (13). SCFA can either be absorbed via the gut epithelium to participate in various physiological processes or excreted in faeces (140). Butyrate is usually the primary source of energy for colonocytes (59), however SCFA may also have an anti-inflammatory role as well as effecting various other metabolic pathways including lipid metabolism and gluconeogenesis (13). Other SCFA such as acetate and propionate enter the portal circulation and are metabolised by the liver, or released into systemic circulation where they are able to bind to vascular endothelium SCFA receptors to influence cardiometabolic health (35). To prevent high concentrations of SCFA in blood, butyrate and propionate are cleared through the portal circulation (15). Increased faecal SCFA levels have been shown to be associated with decreased gut microbiota diversity, higher gut permeability, systemic inflammation, plasma glucose levels, dyslipidaemia, obesity and hypertension even after adjustment for confounders including diet, total calories and physical activity (33). Although they have very important regulatory roles, they also have quantitative roles as catabolic or anabolic substrates for the formation of glucose, cholesterol and lipid metabolism (35).

SCFAs have been shown to exert a positive effect on modulating appetite, obesity and colonic inflammation (34, 49, 51). Despite this, elevated faecal SCFA have been associated with the metabolic syndrome, a risk factor for CVD (46, 151). This was demonstrated in TLR5 knock out mice, where microbiota dysbiosis generated uncontrolled prolonged production of SCFA and promoted development of the metabolic syndrome (136). TLR5 is a flagellin receptor required for gut microbiota homeostasis. In a study where rats were fed a

high fat diet, there was a positive correlation between obesity and the altered abundances of *Phascolarctobacterium*, *Proteus mirabilis* and *Veillonellaceae*, producers of propionate and acetate (79). Dysregulation of SCFA production has recently been suggested to also be a trigger in the aetiology of diabetes in two independent human studies (125, 154). Since SCFA energy is harvested from indigestible fibre, and they can enter the tricarboxylic acid cycle (which also regulates lipogenesis), in hypercaloric diets, an overproduction of SCFAs could result in an undesirable effect.

Gut dysbiosis – links to inflammation and dyslipidaemia

Atherosclerosis is considered a state of chronic inflammation coupled with lipid accumulation in the vessel walls. Systemic activation of the innate immune response as well as within and around the atherosclerotic plaque may enhance plaque progression and rupture. The gut microbiome enhances low grade inflammation in the gut, allowing entry of bacteria and their products into the circulation, triggering chronic inflammation (75). Associations between markers of systemic inflammation including C-reactive protein, interleukin-6 and 8 and tumour necrosis factor- α have been described in humans previously (19). Immune cells within coronary and carotid plaques of patients with ACS, have been shown to produce antibodies against gut microbial produced antigens (*Klebsiella* and *Proteus* strains) (22). Atherosclerotic plaques have their own microbial communities, similar in makeup to the oral cavity and gut (66, 77). However, a recent study has reported no association between atherosclerotic plaque microbial composition and clinical characteristics, contrasting with previous studies (86). These differences in results may be due to several reasons including differing methodologies, differences in population studied as well as population size and diet. As such, further research is highly warranted in this field. Hyperlipidemic ApoE^{-/-} knockout mice exposed to nasal vaccination of outer membrane protein of *Porphyromonas gingivalis*, a gram negative oral cavity bacteria, had reduced atherosclerotic plaques and lower circulating levels of inflammatory cytokines (124).

Dyslipidaemia refers to defects in lipid metabolism, where there is an elevation of plasma cholesterol, low-density lipoprotein-c, triglycerides or both, or a reduction of high-density lipoprotein cholesterol-c levels (97). Lipid levels are in part influenced by genetics, however, are also affected by dietary fat intake, exercise, smoking and alcohol consumption. There is extensive evidence from animal studies, clinical trials and observational epidemiological

studies that outline the causal role of LDL-C in atherosclerosis. Reduction of LDL-C lowers relative risk of major cardiovascular events (116) while HLD-C is inversely associated with risk of coronary heart disease (37). Additionally, the gut microbiome has been positively correlated with lipid and fatty acid metabolism and insulin resistance (14). The human gut is incapable of digesting complex carbohydrates in the form of dietary fibre, thus, it is the specific anaerobic gut bacteria that take on this role via fermentation, to produce SCFA. SCFA are involved in host energy metabolism, regulate intestinal immunity as well as influencing lipid and cholesterol metabolism (36). Host energy homeostasis is mediated by ligand/SCFA interaction with G protein-coupled receptors such as GPR41, expressed primarily in adipose tissue and GPR43, highest levels found in immune cells (17). GPR41 is activated by propionate followed by butyrate and acetate while GPR43 is activated by all three SCFAs at a similar rate (17). Both GPR41 and GPR43 proteins have been found in human colonic tissue (150), white adipose tissue (4), liver and skeletal muscle (17), suggesting that SCFAs may also have an effect on energy metabolism in peripheral tissues. Peptide YY, a gut hormone released postprandially in proportion to the calorie content of a meal and glucagon-like peptide-1 found on beta cells of the pancreas also maintain host energy balance, mainly by appetite reduction and promoting insulin secretion respectively. (9). Thus, it is expected that SCFA overproduction and/or different SCFA profiles can have an impact in metabolic homeostasis in the host (129).

SCFA are also able to mediate fatty acid synthesis and oxidation and lipolysis via peroxisome proliferator-activated receptors, which have roles in carbohydrate, protein and lipid metabolism and tumorigenesis (23). As a result, there is an increase in lipolysis and beta oxidation, thus reducing lipid levels and circulating free fatty acids (24, 34). Apart from SCFA, the gut microbiome can influence lipid levels via the actions of conjugated linoleic acids (CLAs) and BA. Conjugated linoleic acids are produced by *Bifidobacteria*, *Roseburia* and *Lactobacillus* from omega-3 rich dietary sources (106). CLAs influence lipid metabolism by promoting SCFA producing bacteria, creating a cycle of peroxisome proliferator-activated receptor activation (29). BAs modulate hepatic and systemic lipid and glucose metabolism via the FXR (78, 123) or TGR5 (Takeda G protein coupled receptor) (72) receptors. FXR is an important BA receptor, primarily expressed in the liver and intestines, both it and TGR5 plays a major role in carbohydrate and lipid metabolism, specifically, promoting glycogen synthesis and inhibiting gluconeogenesis (28). TGR5 is expressed in brown adipose tissue and muscle, when activated by BAs it promotes glucagon-like peptide-1 release, improving

liver and pancreatic function and enhanced glucose tolerance (152) as well as attenuating diet induced obesity (152).

Microbiota – targeted therapies

In recent years many studies have shown that the composition and diversity of gut microbiota can be beneficially altered by diet, prebiotics, probiotics, and faecal transplantation, to confer benefit to the host.

Dietary intervention

Protein, lipids and carbohydrates are macronutrients which compose the majority of the human diet (117). Dietary habits can influence gut microbiota composition which in turn modulates host health via digestion and absorption of nutrients (127). Microbiota bio-transform dietary substances and synthesise metabolites which travel in the bloodstream to have distal effects on host metabolism and health (31). Reciprocally, diet composition can modulate the composition and function of the gut microbiome (121). Diet provides one of the simplest and easiest ways to modify the microbiome for therapeutic intervention (171). Components such as macronutrients, fibre, polyphenols, prebiotics and probiotics play a crucial role in shaping the gut microbiome, thereby influencing the production and release of gut microbiome metabolites, such as SCFAs (31).

A study linking long term dietary patterns with gut microbial enterotypes demonstrated that intake of animal protein, amino acids and saturated fats were associated with the *Bacteroides* enterotype (171). In contrast, the *Prevotella* enterotype was low in these groups but high for carbohydrates and simple sugars. Vegetarians had an enrichment in the *Prevotella* enterotype. These dietary associations were similar in another study comparing the microbiome of European and Burkina Faso children (32). The microbiome of the European children was dominated by *Bacteroides* associated with the high protein and fat typical of a Western diet. Conversely, the Burkina Faso children's microbiome was the *Prevotella* enterotype as characterised by their typical high carbohydrate and low animal protein diet.

A diet high in vegetables, fruits, grains and legumes and low in red meats and processed carbohydrates – known as the Mediterranean diet, is beneficial in the prevention of CVD (39). This is due to the presence of antioxidants, nitrate and fibre as well as low

saturated/trans fatty acids, sodium and phosphate in this diet. This is likely to cause a reduction in oxidative stress and inflammation, enhanced antioxidant properties and nitric oxide bioavailability and thus modulation of gut microbiota to improve vascular and cardiac function (71). In contrast to the Mediterranean diet, the Western diet, high in saturated fat, is known to increase CVD risk by decreasing gut microbiota diversity and commensal bacteria, such as *Bifidobacterium* (10).

Currently, there is a clear link between the diet and gut microbiome, such that the gut microbiota profile is different between various diets and geographic regions. However, there is still a substantial gap in our understanding of exactly how our diet modulates the gut microbiome and in turn the consequence of the gut microbiota in modulating host health. Further investigations are required as diet provides a low cost and easily manageable strategy in the potential prevention, management and treatment of diseases such as CVD.

Polyphenols

Polyphenols are a large class of aromatic compounds found in plant-based beverages and foods such as apples, berries, citrus, cocoa, tea and coffee (170). There is substantial evidence that a polyphenol rich diet has cardioprotective and anti-diabetic properties (2, 65, 80, 110, 174). Once ingested, polyphenols are broken down, metabolised and absorbed through the role of the gut microbiota (170). Some polyphenols are affected by pH and change in chemical structure thus affecting their bioactivity (45). In addition, many polyphenols undergo hydrolysis via intestinal brush border or microbial enzymes. They may also undergo glucuronidation, methylation and sulfation during intestinal absorption and liver passage (94). There is extensive metabolism of polyphenols by the gut bacteria which will affect their bioavailability and bioactivity (132).

Short term human studies, involving the consumption of tart cherry juice rich in polyphenols, namely anthocyanins and flavonoids, demonstrated the ability of the gut microbiota to ferment polyphenols to influence polyphenol metabolites (98). In the group (n=5) of individuals with a high *Bacteroides* group from low carbohydrate and fibre consumption, drinking tart cherry juice decreased the levels of *Bacteroides* and increased fermentative Firmicutes. In the low *Bacteroides* group (n=5), there was an increase in *Bacteroides* and *Bifidobacterium* (due to polyphenol availability) and a decrease in Firmicutes. Anthocyanins

act as antiplatelet agents in atherosclerosis and CVD prevention, while also inducing nitric oxide formation in the blood vessels, promoting vasodilation (53). Furthermore, individuals consuming a more Western influenced diet, may have a reduced ability to metabolise polyphenols, thus reducing their bioavailability, bioactivity and hence any potential health benefits (98). Similarly, the intake of polyphenols via grape and red wine demonstrated the gut microbiota's ability to promote beneficial microbial communities to enhance host health (104).

Quercetin is a member of the flavonoid family, a subclass of polyphenols and is thought to have antioxidant and anti-inflammatory properties (16, 153). Quercetin administered as a treatment to mice fed a high fat sucrose diet, modified the gut microbiota and attenuated the increase of the Firmicutes/Bacteroidetes ratio (43). Generally, gut microbiota associated with obesity has been associated with a reduced Bacteroidetes to Firmicutes ratio (82, 115). Similarly, quercetin reduced the abundance of *Erysipelotrichaceae* on a family level and at the genus level *Bacillus*, which have been related to the Western diet and weight gain (158). Furthermore, it significantly altered the composition of several bacterial species, increasing the relative abundances of *Bacteroides vulgatus* and *Akkermansia muciniphila* which have been inversely associated with obesity, while reducing *Eubacterium cylindroides* and *Bilophila wadsworthia*, associated with diet-induced obesity (12, 43, 160). A metagenomic study in mice that developed obesity via a high fat sucrose diet demonstrated that the microbiome of high fat sucrose diet fed mice was rich in genes which are associated with sugar uptake for intestinal bacteria (158). Moreover, quercetin improved basal insulin levels (43). This suggests a modulating role of quercetin in altering bacterial profiles to attenuate or improve obesity.

Specific dietary polyphenols have been shown to have beneficial effects on vascular function and attenuation of atherosclerosis. Quercetin and its metabolites have been shown to upregulate adenosine monophosphate-activated protein kinase (AMPK) expression (133). AMPK is an enzyme that plays a role in cellular energy homeostasis and fatty acid oxidation. Quercetin and its metabolites have been shown to protect blood vessels against endothelial dysfunction in intact mouse aortic rings (133). Inhibition of AMPK diminished the positive effects. In human aortic endothelial cells, quercetin and its metabolites induced AMPK and endothelial nitric oxide synthase activation, leading to an increase in nitric oxide, a potent vasodilator (133). In another study, quercetin and theaflavin significantly attenuated

atherosclerotic lesion size in both the aortic sinus and thoracic aorta of ApoE^{-/-} mice through reduction of inflammation, improving nitric oxide bioavailability and inducing heme oxygenase-1, an enzyme that plays a crucial role in prevention of vascular inflammation (88). In mice fed a high fat diet, quercetin protects against oxidant-induced endothelial dysfunction and ApoE^{-/-} mice against atherosclerosis (134). These results provide further reinforcement and support for the cardioprotective effects of quercetin, a dietary polyphenol.

Dietary polyphenols are increasingly recognised as a novel strategy in the potential prevention and treatment of several diseases including CVD and type 2 diabetes. This is explained by the bidirectional relationship which exists between polyphenols and the gut microbiota to influence factors such as blood pressure, endothelial function, insulin sensitivity, thereby promoting cardioprotective and antidiabetic effects. Polyphenols supplemented in the diet at high bioavailability, may improve gut microbiota modulation of CVD and obesity. However, it is recognised that more targeted research activities are still required to resolve the remaining unanswered issues.

Prebiotics, probiotics and synbiotics

Prebiotics are nondigestible food ingredients which promote gut microbiota composition and activity with positive effects on the host (56). They are usually obtained in the diet from fibre rich foods (63) and commonly screened for their ability to increase bifidobacterial numbers. A high fibre diet has been reported to modify the gut microbiota to increase acetate producing bacteria, which contributed to a reduction in gut microbiota dysbiosis and offered cardioprotective effects (95). Acetate is associated with regulating many pathways and genes involved in CVD, such as transcription factor *Egr1*, a regulator of CVD through inflammation, cardiac fibrosis and hypertrophy (95). In contrast, mice fed an atherogenic Paigen diet (mimics inflammation in lean subjects) high in saturated fat and low in fibre, led to the development of the metabolic syndrome including hyperinsulinemia, steatohepatitis, hyperglycaemia and inflammatory infiltration into the aorta, contributing to the development of atherosclerosis via the gut microbiota (112).

Dietary supplementation with an inulin/fructooligosaccharides (FOS) mixture (10 g/day) stimulated Bifidobacterium increase (114) while another study demonstrated the increase in Bifidobacterium following FOS supplementation (149). Beta glucan is another prebiotic

shown to have an influence on lowering cholesterol levels and maintaining blood glucose homeostasis. A study where beta glucan was administered as a dietary intervention over a period of 2 months demonstrated a significant decrease in low density lipoprotein and total cholesterol levels as well as improving endothelial function in healthy individuals thus providing cardioprotective effects, mainly through beneficial SCFA production via the gut microbiome (63). In a recent study involving C57BL6 mice, we demonstrated in a long term dietary supplementation with a combination of isoquercetin, a polyphenol and inulin, a prebiotic, that the development of metabolic syndrome was prevented (144). Compared to mice fed a high fat diet, the mice supplemented with isoquercetin and inulin had attenuated weight gain, improved glucose tolerance, insulin sensitivity, as well as improvements in the gut microbiota composition and functionality and SCFA production (144). Inulin was found to increase faecal SCFA levels of acetate, butyrate and propionate. Animal studies have also demonstrated arabinoxylans as a potential prebiotic due to its role in promoting bifidobacterial and propionate synthesis with beneficial effects on lipid and cholesterol accumulation (105, 159). In humans arabinoxylan oligosaccharides supplemented in the diet increased bacterial populations and butyrate concentrations in faeces (162). Taken together, these findings reinforce the importance of diet in the prevention of CVD and the metabolic syndrome.

Live bacteria, known as probiotics, can be ingested for maintaining or promoting gut microbiota composition (146). Most probiotic products are likely to contain beneficial *Bifidobacteria*, *Lactobacilli*, *Lactococci* and *Streptococci* (7). Probiotics depending on their nature, may inhibit the overgrowth of pathogenic bacteria, stimulates the immune system, modulates pH levels and prevent inflammation (177). Probiotics can improve host metabolism by stimulating digestive enzyme activity and inhibiting bacterial enzyme activity and production of ammonia. *Lactobacillus* and *Bifidobacterium* are beneficial as they improve intestinal barrier function and play a protective role in inflammatory disease (163, 172) by modulating inflammatory and proinflammatory cytokines (such as tumor necrosis factor- α), which may delay and/or improve CVD (62). Probiotics are designed to exert their beneficial effects by restoring the normal composition of microbiota by producing SCFAs (27). *Akkermansia muciniphila* is also known for its probiotic properties and has been demonstrated to be linked with glucose, insulin and leptin which are involved in lipid and glucose metabolism (128). It is also an important modulator of mucus thickness and gut barrier integrity probably due to its close proximity in the mucus layer and closeness to

epithelial cells (108). In a randomized double-blind clinical trial, *Lactobacillus plantarum*, a probiotic, significantly reduced LDL-C and total cholesterol levels and inhibited atherosclerotic plaque formation in hypercholesterolaemic patients (50).

The combination of prebiotics with probiotics for use is known as synbiotics. Synbiotics may further support the growth, survival and persistence of beneficial bacteria as a specific substrate is provided for fermentation by the bacteria (141). Several studies have demonstrated the potential benefits of synbiotics on the gut microbiota and immune functions in chickens (38, 101). In high fat diet mice, symbiotic intervention significantly reduced body weight gain and attenuated features of metabolic syndrome as well as restoring the gut microbial ecosystem structure and function(69).

The studies discussed above have predominately investigated the effects of prebiotics, probiotics and synbiotics on risk factors for cardiovascular disease, such as inflammation, hypertension and effects on glucose and lipid metabolism, as opposed to investigating the direct benefit in atherosclerosis. However, given their beneficial effects on various CVD risk factors, further research investigating how these treatments affect development and progression of atherosclerosis is warranted.

Selective TMAO inhibitors

A recent study was successful in developing a mechanism- based inhibitor drug (3,3-dimethyl-1-butanol), targeting major microbial TMA generating enzymes (CutC/D) where a single oral dose caused a significant reduction in plasma TMAO levels for up to three days as well as reducing enhanced platelet responsiveness and thrombus formation induced by diet (118). This inhibitor is potent, time dependant, irreversible and did not affect other commensals' normal functioning or observable toxicity. When dimethyl-1-butanol was given to atherosclerotic prone ApoE^{-/-} mice on a choline- supplemented diet, plasma TMAO levels significantly reduced, macrophage cholesterol accumulation, foam cell formation and atherosclerotic lesion development were also reduced (166). Microbial protein pairs (CutC and CutD), encoded by genes of the choline utilisation gene cluster (*cut*) have been shown to support choline TMA lyase enzyme activity (96, 119). Current antiplatelet drugs and medication target mammalian enzymes and receptors and have the potential to cause bleeding (52). In contrast, inhibiting microbial generation of TMAO would not suppress platelet

function and therefore, increase the risks of bleeding. This study (118) suggests the selective and nonlethal targeting of specific gut microbiome enzymes which are shown to be linked to disease, thus, limiting systemic exposure of the inhibitor in the host. There is growing evidence of the contributory role of the gut microbiota in health and disease, thus ‘medicating the microbiome’ is at the forefront of clinical potential and could become a common therapy in the future. The development of drugs which inhibit selective gut microbial catabolic pathways mechanistically linked with pathogenesis of disease should be further investigated as a potential therapy for CVD.

Faecal microbiome transplant

Faecal microbiome transplantation refers to the transfer of one’s own or a donor’s faecal sample to a receiver in order to restore gut microbiome dysbiosis and function (146). With more than 70% of gut bacteria colonising the large intestine, they are commonly represented in a stool sample (127). Currently, faecal transplantation is used for treating gastrointestinal disease, such as *Clostridium difficile* infection and inflammatory bowel diseases such as ulcerative colitis (146, 164). Several studies investigated faecal transplantation as a prospect in altering the gut microbiome as a potential therapy for metabolic syndrome and obesity (8, 157). A study involving gut microbial infusion via a gastroduodenal tube in 9 obese and 9 healthy Caucasian males revealed peripheral insulin sensitivity improved after 6 weeks post allogenic gut microbiota infusion (from lean donors) (161). In obese subjects there was a lower microbial diversity in faecal microbiota, with high levels of *Bacteroidetes* and reduced *Clostridium* levels compared to healthy controls. Upon allogenic gut microbial infusion, gut microbiota diversity significantly increased in the obese group, including butyrate producing bacteria *Roseburia intestinalis* which increased 2.5-fold. This suggests a regulating role of butyrate derived from gut microbiota metabolism causing an improvement in insulin sensitivity in obese Caucasian males. Butyrate has been suggested to prevent translocation of endotoxins derived from the gut microbiota, by promoting intestinal mucosa barrier function (25, 81), which has been associated with insulin resistance (25). Increased gut microbiota diversity has also been linked with improved insulin resistance (25). Recently, faecal transplantation from hypertensive mice to germ free mice have demonstrated that high blood pressure is transferrable (1, 70).

There is currently limited evidence on the role of faecal microbiome transplantation in relation to gut microbiota in human patients with CVD, prompting further research in this area in the future. There are also many methodologies and variation in processing, such as, donor choice and testing, faecal microbiome transplantation via upper gastrointestinal tract, enema or colonoscopy, short and long-term monitoring of patients for adverse effects as well as efficacy of treatment (21). These variations mean that faecal microbiome transplantation needs to be regulated before being offered as a suitable treatment option. The clinical use and consequence of faecal transplantation is further limited by news from a recent case involving the severe sepsis and death of two immunocompromised adults after receiving faecal transplantation containing multi-drug resistant organisms (as reported by the FDA). As such, the future use of faecal microbiome transplantation remains challenging.

Future clinical impact of the gut microbiome on CVD

There is mounting evidence that the gut microbiome contributes to both normal health and disease in the host. This provides a novel perspective with far reaching clinical impact. The approach to disease diagnosis, management, treatment and prevention is expanding. Metagenomic sequencing and analysis along with molecular and biochemical methodologies has advanced, allowing identification and characterisation of specific microbiome taxa and their associated metabolites in various samples. Although, on a mechanistic level, much remains to be elucidated. In the future, microbiome profiling of patients through metabolomic /biomarker analysis may be performed to determine the health of the individual, with possible guidance on dietary and lifestyle changes as an approach to targeted intervention. Furthermore, the use of faecal microbiome transplantation, prebiotics and probiotics to manipulate and alter the gut microbial ecology to produce beneficial metabolites to improve host health may provide an alternate adjunct therapy.

Conclusion

Microbiome-host interactions are now understood to be paramount in health and disease susceptibility. There is a mechanistic link between gut microbiota and physiological processes in the body that affect CVD risk. Furthermore, the gut microbiome is a key player at the intersection of diet and CVD via its role in metabolising dietary components and thus, the synthesis and release of important metabolites such as SCFA and TMAO. Current

literature provides evidence that there is a correlation between atherosclerosis and gut microbiome dysbiosis (Figure 4). This change in gut microbiome may contribute to adverse cardiac function resulting in an increase in morbidity and even death. However, it is not clear whether gut microbiome dysbiosis is a contributor and/or consequence of disease. Further research is required in order to characterise the microbiota in healthy individuals and those with CVD. Research into the roles of various metabolites such as SCFA, TMAO and BA and their mechanism of action is also highly warranted as they have been demonstrated to have a vital role in the modulation and influence of host health. As we gain a more comprehensive understanding of the role of the gut microbiota and their metabolites and exactly how they cause the progression and pathogenesis of disease, we may be able to develop advanced diagnostic strategies and potential therapeutic interventions to cater to a more personalised clinical care of patients in the future. Novel therapies including manipulating the diet and using newly designed prebiotic and probiotic options to treat CVD through modulating the gut microbiota and associated metabolites are all gaining traction.

Funding

A. F. Ahmad is currently supported by an Australian Government Research Training Program (RTP) scholarship at the University of Western Australia. G. Dwivedi holds the Wesfarmers Chair in Cardiology at the University of Western Australia.

References

1. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM, et al. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol Genomics*. 2016;49(2):96-104.
2. Ahmad AF, Rich L, Koch H, Croft KD, Ferruzzi MG, Kay CD, et al. Effect of adding milk to black tea on vascular function in healthy men and women: a randomised controlled crossover trial. *Food & function*. 2018;9(12):6307-14.
3. Ahmad AF, Ward NC, Dwivedi G. The gut microbiome and heart failure. *Curr Opin Cardiol*. 2019;34(2):225-32.
4. Al-Lahham SH, Roelofsen H, Priebe M, Weening D, Dijkstra M, Hoek A, et al. Regulation of adipokine production in human adipose tissue by propionic acid. *European journal of clinical investigation*. 2010;40(5):401-7.
5. Armingohar Z, Jorgensen JJ, Kristoffersen AK, Abesha-Belay E, Olsen I. Bacteria and bacterial DNA in atherosclerotic plaque and aneurysmal wall biopsies from patients with and without periodontitis. *J Oral Microbiol*. 2014;6.
6. Arya AK, Hu B. Brain-gut axis after stroke. *Brain circulation*. 2018;4(4):165-73.
7. Azad MAK, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota: An overview. *BioMed Research International*. 2018;2018(8).
8. Backhed F, Manchester J, Semenkovich C, Gordon J. Mechanisms underlying the resistance to diet induced obesity in germ-free mice. *PNAS*. 2007:979-84.
9. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY3-36 physiologically inhibits food intake. *Nature*. 2002;418(6898):650-4.

- 761 10. Battson ML, Lee DM, Jarrell DK, Hou S, Ecton KE, Weir TL, et al. Suppression of
762 gut dysbiosis reverses Western diet-induced vascular dysfunction. *Am J Physiol*
763 *Endocrinol Metab.* 2018;314(5):E468-E77.
- 764 11. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of
765 atherosclerosis : Current view and future perspective on lipoprotein modification
766 treatment. *Neth Heart J.* 2017;25(4):231-42.
- 767 12. Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, et al.
768 Differences in gut microbiota composition between obese and lean children: a cross-
769 sectional study. *Gut Pathogens.* 2013;5(1):10.
- 770 13. Blacher E, Levy M, Tatirovsky E, Elinav E. Microbiome-modulated metabolites at
771 the interface of host immunity. *J Immunol.* 2017;198(2):572-80.
- 772 14. Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of
773 inflammation by microbiota interactions with the host. *Nat Immunol.* 2017;18:851.
- 774 15. Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong
775 CH. Short chain fatty acids exchange across the gut and liver in humans measured at
776 surgery. *Clin Nutr.* 2009;28(6):657-61.
- 777 16. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to
778 nutraceutical. *Eur J Pharmacol.* 2008;585(2-3):325-37.
- 779 17. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al.
780 The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by
781 propionate and other short chain carboxylic acids. *J Biol Chem.* 2003;278(13):11312-
782 9.
- 783 18. Bu J, Wang Z. Cross-talk between gut microbiota and heart via the routes of
784 metabolite and immunity. *Gastroenterology Research and Practice.* 2018;2018:8.

- 785 19. Buford T. (Dis)Trust your gut: The gut microbiome in age-related inflammation,
786 health, and disease. *Microbiome*. 2017;5(1).
- 787 20. Callejo M, Mondejar-Parreño G, Barreira B, Izquierdo-Garcia JL, Morales-Cano D,
788 Esquivel-Ruiz S, et al. Pulmonary arterial hypertension affects the rat gut
789 microbiome. *Scientific Reports*. 2018;8(1):9681.
- 790 21. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al.
791 European consensus conference on faecal microbiota transplantation in clinical
792 practice. *Gut*. 2017;66(4):569.
- 793 22. Canducci F, Saita D, Foglieni C, Piscopiello MR, Chiesa R, Colombo A, et al. Cross-
794 reacting antibacterial auto-antibodies are produced within coronary atherosclerotic
795 plaques of acute coronary syndrome patients (cross-reacting auto-antibodies in
796 atherosclerosis). 2012;7(8):e42283.
- 797 23. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight
798 and insulin sensitivity. *Nature Reviews Endocrinology*. 2015;11:577.
- 799 24. Canfora EE, van der Beek CM, Jocken JWE, Goossens GH, Holst JJ, Olde Damink
800 SWM, et al. Colonic infusions of short-chain fatty acid mixtures promote energy
801 metabolism in overweight/obese men: a randomized crossover trial. *Scientific*
802 *Reports*. 2017;7(1):2360.
- 803 25. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic
804 endotoxemia initiates obesity and insulin resistance. *Diabetes*. 2007;56(7):1761-72.
- 805 26. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions
806 between enteric microbiota, central and enteric nervous systems. *Annals of*
807 *gastroenterology*. 2015;28(2):203-9.
- 808 27. Catinean A, Neag MA, Muntean DM, Bocsan IC, Buzoianu AD. An overview on the
809 interplay between nutraceuticals and gut microbiota. *PeerJ*. 2018;6:e4465.

- 810 28. Chai J, Zou L, Li X, Han D, Wang S, Hu S, et al. Mechanism of bile acid-regulated
811 glucose and lipid metabolism in duodenal-jejunal bypass. *Int J Clin Exp Pathol*.
812 2015;8(12):15778-85.
- 813 29. Chaplin A, Parra P, Serra F, Palou A. Conjugated linoleic acid supplementation under
814 a high-fat diet modulates stomach protein expression and intestinal microbiota in
815 adult mice. *PLoS One*. 2015;10(4):e0125091.
- 816 30. Chen K, Zheng X, Feng MC, Li DL, Zhang HQ. Gut microbiota-dependent
817 metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-
818 induced obese mice. *Front Physiol*. 2017;8:139.
- 819 31. Danneskiold-Samsøe NB, Dias de Freitas Queiroz Barros H, Santos R, Bicas JL,
820 Cazarin CBB, Madsen L, et al. Interplay between food and gut microbiota in health
821 and disease. *Food Res Int*. 2018.
- 822 32. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al.
823 Impact of diet in shaping gut microbiota revealed by a comparative study in children
824 from Europe and rural Africa. *Proc Natl Acad Sci U S A*. 2010;107(33):14691-6.
- 825 33. de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, Velásquez-Mejía EP, Sierra
826 JA, Corrales-Agudelo V, et al. Higher fecal short-chain fatty acid levels are associated
827 with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease
828 risk factors. *Nutrients*. 2018;11(1):51.
- 829 34. den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, et al.
830 Short-chain fatty acids protect against high-fat diet-induced obesity via a
831 PPARgamma-dependent switch from lipogenesis to fat oxidation. *Diabetes*.
832 2015;64(7):2398-408.
- 833 35. den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al.
834 Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and

- lipids. American journal of physiology Gastrointestinal and liver physiology.
2013;305(12):G900-10.
36. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The
role of short-chain fatty acids in the interplay between diet, gut microbiota, and host
energy metabolism. J Lipid Res. 2013;54(9):2325-40.
37. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al.
Major lipids, apolipoproteins, and risk of vascular disease. JAMA.
2009;302(18):1993-2000.
38. Dibaji SM, Seidavi A, Asadpour L, Moreira da Silva F. Effect of a synbiotic on the
intestinal microflora of chickens¹. The Journal of Applied Poultry Research.
2014;23(1):1-6.
39. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al.
2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: A
report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, Part B):2960-84.
40. Eikendal ALM, Groenewegen KA, Anderson TJ, Britton AR, Engström G, Evans
GW, et al. Common carotid intima-media thickness relates to cardiovascular events in
adults aged <45 Years. Hypertension. 2015;65(4):707-13.
41. Elkind MS. Infectious burden: A new risk factor and treatment target for
atherosclerosis. Infect Disord Drug Targets. 2010;10(2):84-90.
42. Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut
microbiota in coronary artery disease patients: A possible link between gut microbiota
and coronary artery disease. Journal of Atherosclerosis and Thrombosis.
2016;23(8):908-21.

- 859 43. Etxeberria U, Arias N, Boque N, Macarulla MT, Portillo MP, Martinez JA, et al.
860 Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and
861 quercetin in high-fat sucrose diet-fed rats. *J Nutr Biochem*. 2015;26(6):651-60.
- 862 44. Fanaroff AC, Rymer JA, Goldstein SA. JAMA Patient Page. Acute Coronary
863 Syndrome. *JAMA*. 2015;314(18):1990.
- 864 45. Fang J. Bioavailability of anthocyanins. *Drug Metab Rev*. 2014;46(4):508-20.
- 865 46. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TMS, Comelli EM. Adiposity, gut
866 microbiota and faecal short chain fatty acids are linked in adult humans. *Nutrition &*
867 *diabetes*. 2014;4(6):e121-e.
- 868 47. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex
869 carbohydrates in the gut. *Gut microbes*. 2012;3(4):289-306.
- 870 48. Fredrik HK, Frida F, Intawat N, Valentina T, Björn F, Dina P, et al. Symptomatic
871 atherosclerosis is associated with an altered gut metagenome. *Nature*
872 *Communications*. 2012;3(1):1245.
- 873 49. Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The
874 short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism.
875 *Nature communications*. 2014;5:3611-.
- 876 50. Fuentes MC, Lajo T, Carrion JM, Cune J. Cholesterol-lowering efficacy of
877 *Lactobacillus plantarum* CECT 7527, 7528 and 7529 in hypercholesterolaemic adults.
878 *Br J Nutr*. 2013;109(10):1866-72.
- 879 51. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al.
880 Commensal microbe-derived butyrate induces the differentiation of colonic regulatory
881 T cells. *Nature*. 2013;504(7480):446-50.
- 882 52. Gachet C. Antiplatelet drugs: which targets for which treatments? *Journal of*
883 *Thrombosis and Haemostasis*. 2015;13(S1):S313-S22.

- 884 53. Gaiz AA, Mosawy S, Colson N, Singh I. Potential of anthocyanin to prevent
885 cardiovascular disease in diabetes. *Alternative therapies in health and medicine*.
886 2018;24(3):40-7.
- 887 54. Gao R, Gao Z, Huang L, Qin H. Gut microbiota and colorectal cancer. *Eur J Clin*
888 *Microbiol Infect Dis*. 2017;36(5):757-69.
- 889 55. Geng J, Yang C, Wang B, Zhang X, Hu T, Gu Y, et al. Trimethylamine N-oxide
890 promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. *Biomed*
891 *Pharmacother*. 2018;97:941-7.
- 892 56. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of
893 the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev*.
894 2004;17(2):259-75.
- 895 57. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm:
896 pathogenesis and implications for management. *Arterioscler Thromb Vasc Biol*.
897 2006;26(12):2605-13.
- 898 58. Golledge J, Norman PE. Pathophysiology of abdominal aortic aneurysm relevant to
899 improvements in patients' management. *Curr Opin Cardiol*. 2009;24(6):532-8.
- 900 59. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review
901 article: the role of butyrate on colonic function. *Alimentary pharmacology &*
902 *therapeutics*. 2008;27(2):104-19.
- 903 60. Hulten E, Preston R, Singh A, Romagnoli C, Ghoshhajra B, Shah R, et al. Obesity,
904 metabolic syndrome and cardiovascular prognosis: from the Partners coronary
905 computed tomography angiography registry. *Cardiovascular Diabetology*. 2017;16(1).
- 906 61. Hyvärinen K, Mäntylä P, Buhlin K, Paju S, Nieminen MS, Sinisalo J, et al. A
907 common periodontal pathogen has an adverse association with both acute and stable
908 coronary artery disease. *Atherosclerosis*. 2012;223(2):478-84.

- 909 62. Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran LG. Probiotic Strain
910 *Lactobacillus casei* BL23 Prevents Colitis-Associated Colorectal Cancer. *Front*
911 *Immunol.* 2017;8:1553.
- 912 63. Jayachandran M, Chen J, Chung SSM, Xu B. A critical review on the impacts of beta-
913 glucans on gut microbiota and human health. *J Nutr Biochem.* 2018;61:101-10.
- 914 64. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in
915 atherosclerotic cardiovascular disease. *Nat Commun.* 2017;8(1):845.
- 916 65. Jumar A, Schmieder RE. Cocoa flavanol cardiovascular effects beyond blood
917 pressure reduction. *J Clin Hypertens (Greenwich).* 2016;18(4):352-8.
- 918 66. Jyoti C-G, Varsha S, Debaleena B, Rahul V, Neeraj P, Balram B, et al. Linkages
919 between oral commensal bacteria and atherosclerotic plaques in coronary artery
920 disease patients. *npj Biofilms and Microbiomes.* 2016;2(1):1.
- 921 67. Kabat AM, Srinivasan N, Maloy KJ. Modulation of immune development and
922 function by intestinal microbiota. *Trends Immunol.* 2014;35(11):507-17.
- 923 68. Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al.
924 Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nat*
925 *Commun.* 2012;3:1245.
- 926 69. Ke X, Walker A, Haange S-B, Lagkouvardos I, Liu Y, Schmitt-Kopplin P, et al.
927 Synbiotic-driven improvement of metabolic disturbances is associated with changes
928 in the gut microbiome in diet-induced obese mice. *Molecular Metabolism.*
929 2019;22:96-109.
- 930 70. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on Fecal
931 Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and
932 Outlook. *Gastroenterology.* 2015;149(1):223-37.

- 933 71. Kerley CP. Dietary patterns and components to prevent and treat heart failure: A
934 comprehensive review of human studies. *Nutr Res Rev.* 2018;1-27.
- 935 72. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut
936 microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid
937 receptor GPR43. *Nature Communications.* 2013;4:1829.
- 938 73. Kitai T, Tang WHW. Gut microbiota in cardiovascular disease and heart failure. *Clin*
939 *Sci (Lond).* 2018;132(1):85-91.
- 940 74. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal
941 microbiota metabolism of L-carnitine, a nutrient in red meat, promotes
942 atherosclerosis. *Nat Med.* 2013;19(5):576-85.
- 943 75. Komaroff AL. The microbiome and risk for atherosclerosis. *Jama-J Am Med Assoc.*
944 2018;319(23):2381-2.
- 945 76. Koopen AM, Groen AK, Nieuwdorp M. Human microbiome as therapeutic
946 intervention target to reduce cardiovascular disease risk. *Curr Opin Lipidol.*
947 2016;27(6):615-22.
- 948 77. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, et al. Human oral, gut,
949 and plaque microbiota in patients with atherosclerosis. *Proceedings of the National*
950 *Academy of Sciences of the United States of America.* 2011;108(-):4592.
- 951 78. Lau K, Srivatsav V, Rizwan A, Nashed A, Liu R, Shen R, et al. Bridging the gap
952 between gut microbial dysbiosis and cardiovascular diseases. *Nutrients.* 2017;9:859-
953 74.
- 954 79. Lecomte V, Kaakoush NO, Maloney CA, Raipuria M, Huinao KD, Mitchell HM, et
955 al. Changes in gut microbiota in rats fed a high fat diet correlate with obesity-
956 associated metabolic parameters. *PLoS One.* 2015;10(5):e0126931.

- 957 80. Lee AH, Tan L, Hiramatsu N, Ishisaka A, Alfonso H, Tanaka A, et al. Plasma
958 concentrations of coffee polyphenols and plasma biomarkers of diabetes risk in
959 healthy Japanese women. *Nutr Diabetes*. 2016;6:e212.
- 960 81. Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM.
961 Enhanced translocation of bacteria across metabolically stressed epithelia is reduced
962 by butyrate. *Inflammatory bowel diseases*. 2010;16(7):1138-48.
- 963 82. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity
964 alters gut microbial ecology. *Proc Natl Acad Sci U S A*. 2005;102(31):11070-5.
- 965 83. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis
966 contributes to the development of hypertension. *Microbiome*. 2017;5(1):14-.
- 967 84. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota-
968 dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker
969 for incident cardiovascular events beyond traditional risk factors. *European Heart*
970 *Journal*. 2017;38(11):814-24.
- 971 85. Liao Y-F, Zhu W, Li D-P, Zhu X. Heme oxygenase-1 and gut ischemia/reperfusion
972 injury: A short review. *World J Gastroenterol*. 2013;19(23):3555-61.
- 973 86. Lindskog Jonsson A, Hållénus FF, Akrami R, Johansson E, Wester P, Arnerlov C.
974 Bacterial profile in human atherosclerotic plaques. *Journal of Vascular Surgery*.
975 2017;66(5):1625-.
- 976 87. Liu C, Zhang J, Li M, Zhao L, Ji C, Ma Q. Alterations and structural resilience of the
977 gut microbiota under dietary fat perturbations. *The Journal of Nutritional*
978 *Biochemistry*. 2018;61:91-100.
- 979 88. Loke WM, Proudfoot JM, Hodgson JM, McKinley AJ, Hime N, Magat M, et al.
980 Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout

- 981 mice by alleviating inflammation and endothelial dysfunction. *Arterioscler Thromb*
982 *Vasc Biol.* 2010;30(4):749-57.
- 983 89. Lopez-Siles M, Martinez-Medina M, Surís-Valls R, Aldeguer X, Sabat-Mir M,
984 Duncan SH, et al. Changes in the abundance of *Faecalibacterium prausnitzii*
985 phylogroups I and II in the intestinal mucosa of inflammatory bowel disease and
986 patients with colorectal cancer. *Inflammatory bowel diseases.* 2015;22(1):28-41.
- 987 90. Loscalzo J. Gut microbiota, the genome, and diet in atherogenesis. *N Engl J Med.*
988 2013;368(17):1647-9.
- 989 91. Lund Haheim L, Olsen I, Nafstad P, Schwarze P, Ronningen KS. Antibody levels to
990 single bacteria or in combination evaluated against myocardial infarction. *J Clin*
991 *Periodontol.* 2008;35(6):473-8.
- 992 92. Ma G, Pan B, Chen Y, Guo C, Zhao M, Zheng L, et al. Trimethylamine N-oxide in
993 atherogenesis: Impairing endothelial self-repair capacity and enhancing monocyte
994 adhesion. *Bioscience Reports.* 2017;37(2):BSR20160244.
- 995 93. Machiels K, Joossens M, Sabino J, De Preter V, Arijis I, Eeckhaut V, et al. A decrease
996 of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii*
997 defines dysbiosis in patients with ulcerative colitis. *Gut.* 2014;63(8):1275.
- 998 94. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: Food sources
999 and bioavailability. *Am J Clin Nutr.* 2004;79(5):727-47.
- 1000 95. Marques ZF, Nelson KE, Chu WP-Y, Horlock RD, Fiedler MA, Ziemann MM, et al.
1001 High-fiber diet and acetate supplementation change the gut microbiota and prevent
1002 the development of hypertension and heart failure in hypertensive mice. *Circulation.*
1003 2017;135(10):964-77.

- 1004 96. Martínez-del Campo A, Bodea S, Hamer HA, Marks JA, Haiser HJ, Turnbaugh PJ, et
1005 al. Characterization and detection of a widely distributed gene cluster that predicts
1006 anaerobic choline utilization by human gut bacteria. *mBio*. 2015;6(2):e00042-15.
- 1007 97. Matey-Hernandez ML, Williams FMK, Potter T, Valdes AM, Spector TD, Menni C.
1008 Genetic and microbiome influence on lipid metabolism and dyslipidemia. *Physiol*
1009 *Genomics*. 2018;50(2):117-26.
- 1010 98. Mayta-Apaza AC, Pottgen E, De Bodt J, Papp N, Marasini D, Howard L, et al. Impact
1011 of tart cherries polyphenols on the human gut microbiota and phenolic metabolites in
1012 vitro and in vivo. *The Journal of Nutritional Biochemistry*. 2018;59:160-72.
- 1013 99. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents
1014 intestinal inflammatory disease. *Nature*. 2008;453(7195):620-5.
- 1015 100. Minnifield B, Aslibekyan S. The interplay between the microbiome and
1016 cardiovascular risk. *Current Genetic Medicine Reports*. 2018;6(2):89-97.
- 1017 101. Mookiah S, Sieo CC, Ramasamy K, Abdullah N, Ho YW. Effects of dietary
1018 prebiotics, probiotic and synbiotics on performance, caecal bacterial populations and
1019 caecal fermentation concentrations of broiler chickens. *J Sci Food Agric*.
1020 2014;94(2):341-8.
- 1021 102. Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future
1022 therapeutics in treating inflammatory and infectious diseases: Lessons from recent
1023 findings. *The Journal of Nutritional Biochemistry*. 2018;61:111-28.
- 1024 103. Nadatani Y, Watanabe T, Shimada S, Otani K, Tanigawa T, Fujiwara Y. Microbiome
1025 and intestinal ischemia/reperfusion injury. *J Clin Biochem Nutr*. 2018;63(1):26-32.
- 1026 104. Nash V, Ranadheera CS, Georgousopoulou EN, Mellor DD, Panagiotakos DB,
1027 McKune AJ, et al. The effects of grape and red wine polyphenols on gut microbiota -
1028 A systematic review. *Food Res Int*. 2018;113:277-87.

- 1029 105. Neyrinck AM, Possemiers S, Druart C, Van de Wiele T, De Backer F, Cani PD, et al.
1030 Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria,
1031 Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PLoS One.
1032 2011;6(6):e20944.
- 1033 106. Noriega BS, Sanchez-Gonzalez MA, Salyakina D, Coffman J. Understanding the
1034 Impact of Omega-3 Rich Diet on the Gut Microbiota. Case Reports in Medicine.
1035 2016;2016:6.
- 1036 107. Ott SJ, Mokhtari NEE, Musfeldt M, Hellmig S, Freitag S, Rehman A, et al. Detection
1037 of diverse bacterial signatures in atherosclerotic lesions of patients with coronary
1038 heart disease. Circulation. 2006;113(7):929-37.
- 1039 108. Ottman N, Reunanen J, Meijerink M, Pietila TE, Kainulainen V, Klievink J, et al.
1040 Pili-like proteins of Akkermansia muciniphila modulate host immune responses and
1041 gut barrier function. PLoS One. 2017;12(3):e0173004.
- 1042 109. Owczuk R, Dylczyk-Sommer A, Wojciechowski J, Paszkiewicz M, Wujtewicz M,
1043 Stepnowski P, et al. The influence of epidural blockade on gut permeability in
1044 patients undergoing open surgical repair of abdominal aortic aneurysm.
1045 Anaesthesiology intensive therapy. 2016;48(2):122-7.
- 1046 110. Pang J, Zhang Z, Zheng TZ, Bassig BA, Mao C, Liu X, et al. Green tea consumption
1047 and risk of cardiovascular and ischemic related diseases: A meta-analysis. Int J
1048 Cardiol. 2016;202:967-74.
- 1049 111. Pedicino D, Severino A, Ucci S, Bugli F, Flego D, Giglio AF, et al. Epicardial
1050 adipose tissue microbial colonization and inflammasome activation in acute coronary
1051 syndrome. Int J Cardiol. 2017;236:95-9.

- 1052 112. Pindjakova J, Sartini C, Lo Re O, Rappa F, Coupe B, Lelouvier B, et al. Gut dysbiosis
1053 and adaptive immune response in diet-induced obesity vs. systemic inflammation.
1054 *Frontiers in Microbiology*. 2017;8(1157).
- 1055 113. Rafieian-Kopaei M, Setorki M, Douudi M, Baradaran A, Nasri H. Atherosclerosis:
1056 process, indicators, risk factors and new hopes. *International journal of preventive*
1057 *medicine*. 2014;5(8):927-46.
- 1058 114. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin
1059 on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and
1060 *Faecalibacterium prausnitzii*. *Br J Nutr*. 2009;101(4):541-50.
- 1061 115. Rastmanesh R. High polyphenol, low probiotic diet for weight loss because of
1062 intestinal microbiota interaction. *Chem-Biol Interact*. 2011;189(1):1-8.
- 1063 116. Reklou A, Doumas M, Imprialos K, Stavropoulos K, Patoulis D, Athyros VG.
1064 Reduction of vascular inflammation, LDL-C, or both for the protection from
1065 cardiovascular events? *Open Cardiovasc Med J*. 2018;12:29-40.
- 1066 117. Riaz Rajoka MS, Shi J, Mehwish HM, Zhu J, Li Q, Shao D, et al. Interaction between
1067 diet composition and gut microbiota and its impact on gastrointestinal tract health.
1068 *Food Science and Human Wellness*. 2017;6(3):121-30.
- 1069 118. Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, et al. Development of a gut
1070 microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. *Nat Med*.
1071 2018;24(9):1407-17.
- 1072 119. Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota
1073 composition modulates choline bioavailability from diet and accumulation of the
1074 proatherogenic metabolite trimethylamine-N-oxide. *mBio*. 2015;6(2):e02481-14.

- 1075 120. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: Update on the potential
1076 contribution of multiple infectious organisms to the pathogenesis of atherosclerosis.
1077 Thrombosis and haemostasis. 2011;106(5):858-67.
- 1078 121. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al.
1079 Environment dominates over host genetics in shaping human gut microbiota. Nature.
1080 2018;555(7695):210-5.
- 1081 122. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota
1082 functions: Metabolism of nutrients and other food components. European Journal of
1083 Nutrition. 2018;57(1):1-24.
- 1084 123. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A,
1085 Karns R, et al. FXR is a molecular target for the effects of vertical sleeve
1086 gastrectomy. Nature. 2014;509:183.
- 1087 124. Saita D, Ferrarese R, Foglieni C, Esposito A, Canu T, Perani L, et al. Adaptive
1088 immunity against gut microbiota enhances apoE-mediated immune regulation and
1089 reduces atherosclerosis and western-diet-related inflammation. Scientific Reports.
1090 2016;6:29353.
- 1091 125. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vila AV, Vosa U, et al. Causal
1092 relationships among the gut microbiome, short-chain fatty acids and metabolic
1093 diseases. Nat Genet. 2019;51(4):600-+.
- 1094 126. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut
1095 microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-
1096 muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225-
1097 35.

- 1098 127. Schiattarella GG, Sannino A, Esposito G, Perrino C. Diagnostics and therapeutic
1099 implications of gut microbiota alterations in cardiometabolic diseases. Trends
1100 Cardiovasc Med. 2019;29(3):141-7.
- 1101 128. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S,
1102 Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of
1103 inflammation, altered adipose tissue metabolism and metabolic disorders during
1104 obesity in mice. Scientific Reports. 2015;5:16643.
- 1105 129. Schönfeld P, Wojtczak L. Short- and medium-chain fatty acids in energy metabolism:
1106 the cellular perspective. J Lipid Res. 2016;57(6):943-54.
- 1107 130. Seldin Marcus M, Meng Y, Qi H, Zhu W, Wang Z, Hazen Stanley L, et al.
1108 Trimethylamine N-oxide promotes vascular inflammation through signaling of
1109 mitogen-activated protein kinase and nuclear factor- κ B. Journal of the American
1110 Heart Association. 2016;5(2):e002767.
- 1111 131. Senthong V, Wang Z, Fan Y, Wu Y, Hazen SL, Tang WH. Trimethylamine N-oxide
1112 and mortality risk in patients with peripheral artery disease. J Am Heart Assoc.
1113 2016;5(10).
- 1114 132. Serra D, Almeida LM, Dinis TCP. Dietary polyphenols: A novel strategy to modulate
1115 microbiota-gut-brain axis. Trends Food Sci Technol. 2018;78:224-33.
- 1116 133. Shen Y, Croft KD, Hodgson JM, Kyle R, Lee IL, Wang Y, et al. Quercetin and its
1117 metabolites improve vessel function by inducing eNOS activity via phosphorylation
1118 of AMPK. Biochem Pharmacol. 2012;84(8):1036-44.
- 1119 134. Shen Y, Ward NC, Hodgson JM, Puddey IB, Wang Y, Zhang D, et al. Dietary
1120 quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in
1121 apolipoprotein E knockout mice fed a high-fat diet: a critical role for heme
1122 oxygenase-1. Free radical biology & medicine. 2013;65:908-15.

- 1123 135. Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut
1124 microbiota. *Trends Biotechnol.* 2015;33(9):496-503.
- 1125 136. Singh V, Chassaing B, Zhang L, San Yeoh B, Xiao X, Kumar M, et al. Microbiota-
1126 dependent hepatic lipogenesis mediated by stearyl CoA desaturase 1 (SCD1)
1127 promotes metabolic syndrome in TLR5-deficient mice. *Cell Metab.* 2015;22(6):983-
1128 96.
- 1129 137. Singh V, Roth S, Llovera G, Sadler R, Garzetti D, Stecher B, et al. Microbiota
1130 dysbiosis controls the neuroinflammatory response after stroke. *J Neurosci.*
1131 2016;36(28):7428-40.
- 1132 138. Singh V, Yeoh BS, Vijay-Kumar M. Gut microbiome as a novel cardiovascular
1133 therapeutic target. *Curr Opin Pharm.* 2016;27:8-12.
- 1134 139. Smolinska A, Tedjo DI, Blanchet L, Bodelier A, Pierik MJ, Masclee AAM, et al.
1135 Volatile metabolites in breath strongly correlate with gut microbiome in CD patients.
1136 *Anal Chim Acta.* 2018;1025:1-11.
- 1137 140. Stumpff F. A look at the smelly side of physiology: transport of short chain fatty
1138 acids. *Pflugers Archiv : European journal of physiology.* 2018;470(4):571-98.
- 1139 141. Sugiharto S. Role of nutraceuticals in gut health and growth performance of poultry.
1140 *Journal of the Saudi Society of Agricultural Sciences.* 2016;15(2):99-111.
- 1141 142. Sun X, Jiao X, Ma Y, Liu Y, Zhang L, He Y, et al. Trimethylamine N-oxide induces
1142 inflammation and endothelial dysfunction in human umbilical vein endothelial cells
1143 via activating ROS-TXNIP-NLRP3 inflammasome. *Biochem Biophys Res Commun.*
1144 2016;481(1):63-70.
- 1145 143. Suzuki T, Heaney LM, Jones DJL, Ng LL. Trimethylamine N-oxide and risk
1146 stratification after acute myocardial infarction. *Clin Chem.* 2017;63(1):420.

- 1147 144. Tan S, Caparros-Martin JA, Matthews VB, Koch H, O’Gara F, Croft KD, et al.
1148 Isoquercetin and inulin synergistically modulate the gut microbiome to prevent
1149 development of the metabolic syndrome in mice fed a high fat diet. *Scientific Reports*.
1150 2018;8(1):10100.
- 1151 145. Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in
1152 cardiovascular health and disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*.
1153 2019;73(16):2089-105.
- 1154 146. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease.
1155 *Circ Res*. 2017;120(7):1183-96.
- 1156 147. Tang WHW, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic
1157 value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-
1158 oxide in patients with heart failure: Refining the gut hypothesis. *J Am Coll Cardiol*.
1159 2014;64(18):1908-14.
- 1160 148. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal
1161 microbial metabolism of phosphatidylcholine and cardiovascular risk. *New Engl J*
1162 *Med*. 2013;368(17):1575-84.
- 1163 149. Tannock GW, Munro K, Bibiloni R, Simon MA, Hargreaves P, Gopal P, et al. Impact
1164 of consumption of oligosaccharide-containing biscuits on the fecal microbiota of
1165 humans. *Appl Environ Microbiol*. 2004;70(4):2129-36.
- 1166 150. Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M, et al. Expression of
1167 short-chain fatty acid receptor GPR41 in the human colon. *Biomedical research*
1168 (Tokyo, Japan). 2009;30(3):149-56.
- 1169 151. Teixeira TF, Grzeskowiak L, Franceschini SC, Bressan J, Ferreira CL, Peluzio MC.
1170 Higher level of faecal SCFA in women correlates with metabolic syndrome risk
1171 factors. *Br J Nutr*. 2013;109(5):914-9.

- 1172 152. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated
1173 bile acid sensing controls glucose homeostasis. *Cell Metab.* 2009;10(3):167-77.
- 1174 153. Timmers S, Hesselink MKC, Schrauwen P. Therapeutic potential of resveratrol in
1175 obesity and type 2 diabetes: new avenues for health benefits? *Ann N Y Acad Sci.*
1176 2013;1290(1):83-9.
- 1177 154. Tirosh A, Calay ES, Tuncman G, Claiborn KC, Inouye KE, Eguchi K, et al. The
1178 short-chain fatty acid propionate increases glucagon and FABP4 production,
1179 impairing insulin action in mice and humans. *Sci Transl Med.* 2019;11(489).
- 1180 155. Toghiani BJ, Saratzis A, Bown MJ. Abdominal aortic aneurysm-an independent disease
1181 to atherosclerosis? *Cardiovascular pathology : the official journal of the Society for*
1182 *Cardiovascular Pathology.* 2017;27:71-5.
- 1183 156. Trøseid M, Ueland T, Hov JR, Svardsdal A, Gregersen I, Dahl CP, et al. Microbiota-
1184 dependent metabolite trimethylamine-N-oxide is associated with disease severity and
1185 survival of patients with chronic heart failure. *Journal of Internal Medicine.*
1186 2015;277(6):717-26.
- 1187 157. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An
1188 obesity-associated gut microbiome with increased capacity for energy harvest. *Nature.*
1189 2006;444(7122):1027.
- 1190 158. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet
1191 on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic
1192 mice. *Sci Transl Med.* 2009;1(6):6ra14.
- 1193 159. Van den Abbeele P, Gerard P, Rabot S, Bruneau A, El Aidy S, Derrien M, et al.
1194 Arabinosylans and inulin differentially modulate the mucosal and luminal gut
1195 microbiota and mucin-degradation in humanized rats. *Environ Microbiol.*
1196 2011;13(10):2667-80.

- 1197 160. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, et al. Human
1198 intestinal microbiota composition is associated with local and systemic inflammation
1199 in obesity. *Obesity*. 2013;21(12):E607-E15.
- 1200 161. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al.
1201 Transfer of intestinal microbiota from lean donors increases insulin sensitivity in
1202 individuals with metabolic syndrome. *Gastroenterology*. 2012;143(4):913-6.e7.
- 1203 162. Walton GE, Lu C, Trogh I, Arnaut F, Gibson GR. A randomised, double-blind,
1204 placebo controlled cross-over study to determine the gastrointestinal effects of
1205 consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers.
1206 *Nutrition Journal*. 2012;11(1):36.
- 1207 163. Wang H, Zhang W, Zuo L, Zhu W, Wang B, Li Q, et al. Bifidobacteria may be
1208 beneficial to intestinal microbiota and reduction of bacterial translocation in mice
1209 following ischaemia and reperfusion injury. *Br J Nutr*. 2013;109(11):1990-8.
- 1210 164. Wang J-W, Kuo C-H, Kuo F-C, Wang Y-K, Hsu W-H, Yu F-J, et al. Fecal microbiota
1211 transplantation: Review and update. *J Formosan Med Assoc*. 2019;118:S23-S31.
- 1212 165. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, et al. Gut flora
1213 metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*.
1214 2011;472:57.
- 1215 166. Wang Z, Roberts Adam B, Buffa Jennifer A, Levison Bruce S, Zhu W, Org E, et al.
1216 Non-lethal inhibition of gut microbial trimethylamine production for the treatment of
1217 atherosclerosis. *Cell*. 2015;163(7):1585-95.
- 1218 167. Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and
1219 disease. *Protein & Cell*. 2018;9(5):416-31.
- 1220 168. Wasserberg N, Pileggi A, Salgar SK, Ruiz P, Ricordi C, Inverardi L, et al. Heme
1221 oxygenase-1 upregulation protects against intestinal ischemia/reperfusion injury: a

- laboratory based study. International journal of surgery (London, England).
2007;5(4):216-24.
169. Wen SW, Wong CHY. An unexplored brain-gut microbiota axis in stroke. Gut
microbes. 2017;8(6):601-6.
170. Williamson G. The role of polyphenols in modern nutrition. Nutrition bulletin.
2017;42(3):226-35.
171. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking
long-term dietary patterns with gut microbial enterotypes. Science.
2011;334(6052):105-8.
172. Xue L, He J, Gao N, Lu X, Li M, Wu X, et al. Probiotics may delay the progression
of nonalcoholic fatty liver disease by restoring the gut microbiota structure and
improving intestinal endotoxemia. Scientific Reports. 2017;7:45176.
173. Yamashiro K, Tanaka R, Urabe T, Ueno Y, Yamashiro Y, Nomoto K, et al. Gut
dysbiosis is associated with metabolism and systemic inflammation in patients with
ischemic stroke. PloS one. 2017;12(2):e0171521-e.
174. Yang J, Mao QX, Xu HX, Ma X, Zeng CY. Tea consumption and risk of type 2
diabetes mellitus: a systematic review and meta-analysis update. BMJ Open.
2014;4(7):e005632.
175. Yang X, Xie L, Li Y, Wei C. More than 9,000,000 Unique Genes in Human Gut
Bacterial Community: Estimating Gene Numbers Inside a Human Body2009. e6074
p.
176. Yokota A, Fukiya S, Islam KBMS, Ooka T, Ogura Y, Hayashi T, et al. Is bile acid a
determinant of the gut microbiota on a high-fat diet? Gut microbes. 2012;3(5):455-9.
177. Zabell A, Tang W. Targeting the microbiome in heart failure. Current Treatment
Options in Cardiovascular Medicine. 2017;19(4):1-12.

- 1247 178. Zeisel SH, Warrier M. Trimethylamine N -oxide, the microbiome, and heart and
1248 kidney disease. *Annu Rev Nutr.* 2017;37(1):157-81.
- 1249 179. Zeng X, Gao X, Peng Y, Wu Q, Zhu J, Tan C, et al. Higher risk of stroke is correlated
1250 with increased opportunistic pathogen load and reduced levels of butyrate-producing
1251 bacteria in the gut. *Frontiers in Cellular and Infection Microbiology.* 2019;9(4).
- 1252 180. Zhu Q, Gao R, Zhang Y, Pan D, Zhu Y, Zhang X, et al. Dysbiosis signatures of gut
1253 microbiota in coronary artery disease. *Physiol Genomics.* 2018;50(10):893-903.
- 1254 181. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial
1255 metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. *Cell.*
1256 2016;165(1):111-24.
- 1257 182. Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine N-
1258 oxide from dietary choline Is prothrombotic in subjects. *Circulation.*
1259 2017;135(17):1671-3.
- 1260

1261 **Tables, Figures and Figure Legends**

1262

1263 **Table 1:** Summary of studies investigating associations between the gut microbiome and CVD.

Reference	Method	Number of subjects	Disease status	Main findings
(121)	16S rRNA & metagenome sequencing	N =1046	Plasma lipids, Glycaemic traits	Microbiota predominantly shaped by non-genetic factors and explain \geq % variance in HDL, fasting glucose, obesity
(64)	Metagenome shotgun sequencing	N =218 CVD N =187 controls	Atherosclerosis	In CVD, increased <i>Enterobacteriaceae</i> & <i>Streptococcus</i>
(83)	16S rRNA	N =56 pre-hypertensive N =99 hypertensive N =41 controls	Hypertension	Reduced bacterial diversity Overgrowth of <i>Prevotella/Klebsiella</i> in prehypertension and hypertension compared to controls
(61)	qPCR	N =179 CAD N =166 ACS N =119 controls	CAD	<i>Aggregatibacter actinomycetemcomitans</i> levels linked with risk for CAD
(68)	MEDUSA	N =12 symptomatic atherosclerosis	Atherosclerosis	<i>Collinsella</i> genus higher in symptomatic AS

		N=13 controls	<i>Eubacterium</i> & <i>Roseburia</i> higher in controls	
(77)	qPCR	N =15 CVD	Atherosclerosis	Overgrowth of <i>Veillonella</i> and
	16S rRNA	N =15 controls		<i>Streptococcus</i> in atherosclerotic plaque samples

1264 16S rRNA: 16S ribosomal ribonucleic acid, HDL: High density lipoprotein, CVD: cardiovascular disease, qPCR: quantitative polymerase chain reaction, CAD:
 1265 coronary artery disease, ACS: acute coronary syndrome, MEDUSA: Metagenomic Data Utilization and Analysis.

1266





Figure 1: Relative distribution of the five main bacterial phyla found in the gut obtained from the RDP (ribosomal database project) browser. Firmicutes and Bacteroidetes compose 65% and 30% of the gut respectively. *Others* include the remaining phyla: Spirochaetes, Fusobacteria, Deferribacteres, Cyanobacteria, Planctomycetes, Lentisphaerae, TM7 and Tenericutes. Adapted from (175).

1273



1274

1275 **Figure 2:** Cardiovascular disease manifestations in which gut microbiota and their associated
1276 metabolites are altered. BA: bile acid, SCFA: short chain fatty acid, TMAO: Trimethylamine-
1277 N- oxide.

1278

1279




Figure 3: Interactions between diet and the gut microbiota to form metabolites such as SCFA and TMAO, which play a crucial role in host health and cardiovascular risk. CVD: cardiovascular disease, FMO3: Flavin monooxygenase 3, GPCR: G protein coupled receptor, PBA: primary bile acid, SBA: secondary bile acid, SCFA: short chain fatty acid, TMA: Trimethylamine, TMAO: Trimethylamine- N- oxide.




Figure 4: The complex relationship between dietary components ingested and other factors, affecting the gut microbiota, whose composition then influences their functionality and metabolite production and release. A disruption to which leads to dysbiosis, thereby affecting host health and the progression and pathogenesis of various cardiovascular diseases in a vicious cycle. ATP: Adenosine triphosphate, BA: bile acid, CO₂: carbon dioxide, CH₄: methane, CVD: cardiovascular disease, H₂S: hydrogen sulphide, PBA: primary bile acid, ROS: reactive oxygen species, SBA: secondary bile acid, SCFA: short chain fatty acid, TMAO: Trimethylamine- N- oxide.

Tables, Figures and Figure Legends

Table 1: Summary of studies investigating associations between the gut microbiome and CVD.

Reference	Method	Number of subjects	Disease status	Main findings
(117)	16S rRNA & metagenome sequencing	N =1046	Plasma lipids, Glycaemic traits	Microbiota predominantly shaped by non-genetic factors and explain \geq % variance in HDL, fasting glucose, obesity
(60)	Metagenome shotgun sequencing	N =218 CVD N =187 controls	Atherosclerosis	In CVD, increased <i>Enterobacteriaceae</i> & <i>Streptococcus</i>
(79)	16S rRNA	N =56 pre-hypertensive N =99 hypertensive N =41 controls	Hypertension	Reduced bacterial diversity Overgrowth of <i>Prevotella/Klebsiella</i> in prehypertension and hypertension compared to controls
(57)	qPCR	N =179 CAD N =166 ACS N =119 controls	CAD	<i>Aggregatibacter actinomycetemcomitans</i> levels linked with risk for CAD
(64)	MEDUSA	N =12 symptomatic atherosclerosis	Atherosclerosis	<i>Collinsella</i> genus higher in symptomatic AS

		N=13 controls		<i>Eubacterium</i> & <i>Roseburia</i> higher in controls
(73)	qPCR	N =15 CVD	Atherosclerosis	Overgrowth of <i>Veillonella</i> and
	16S rRNA	N =15 controls		<i>Streptococcus</i> in atherosclerotic plaque samples

16S rRNA: 16S ribosomal ribonucleic acid, HDL: High density lipoprotein, CVD: cardiovascular disease, qPCR: quantitative polymerase chain reaction, CAD: coronary artery disease, ACS: acute coronary syndrome, MEDUSA: Metagenomic Data Utilization and Analysis.




Figure 1: Relative distribution of the five main bacterial phyla found in the gut obtained from the RDP (ribosomal database project) browser. Firmicutes and Bacteroidetes compose 65% and 30% of the gut respectively. *Others* include the remaining phyla: Spirochaetes, Fusobacteria, Deferribacteres, Cyanobacteria, Planctomycetes, Lentisphaerae, TM7 and Tenericutes. Adapted from (170).




Figure 2: Cardiovascular disease manifestations in which gut microbiota and their associated metabolites are altered. BA: bile acid, SCFA: short chain fatty acid, TMAO: Trimethylamine-N- oxide.




Figure 3: Interactions between diet and the gut microbiota to form metabolites such as SCFA and TMAO, which play a crucial role in host health and cardiovascular risk. CVD: cardiovascular disease, FMO3: Flavin monooxygenase 3, GPCR: G protein coupled receptor, PBA: primary bile acid, SBA: secondary bile acid, SCFA: short chain fatty acid, TMA: Trimethylamine, TMAO: Trimethylamine- N- oxide.




Figure 4: The complex relationship between dietary components ingested and other factors, affecting the gut microbiota, whose composition then influences their functionality and metabolite production and release. A disruption to which leads to dysbiosis, thereby affecting host health and the progression and pathogenesis of various cardiovascular diseases in a vicious cycle. ATP: Adenosine triphosphate, BA: bile acid, CO₂: carbon dioxide, CH₄: methane, CVD: cardiovascular disease, H₂S: hydrogen sulphide, PBA: primary bile acid, ROS: reactive oxygen species, SBA: secondary bile acid, SCFA: short chain fatty acid, TMAO: Trimethylamine- N- oxide.